Elanix Biotechnologies AG (FRA:ELN) Total Liabilities : €2.48 Mil (As of Dec. 2018)

View and export this data going back to . Start your Free Trial

What is Elanix Biotechnologies AG Total Liabilities?

Elanix Biotechnologies AG's Total Liabilities for the quarter that ended in Dec. 2018 was €2.48 Mil.

Elanix Biotechnologies AG's quarterly Total Liabilities increased from Dec. 2017 (€1.93 Mil) to Jun. 2018 (€6.32 Mil) but then declined from Jun. 2018 (€6.32 Mil) to Dec. 2018 (€2.48 Mil).

Elanix Biotechnologies AG's annual Total Liabilities declined from Dec. 2016 (€6.37 Mil) to Dec. 2017 (€1.93 Mil) but then increased from Dec. 2017 (€1.93 Mil) to Dec. 2018 (€2.48 Mil).

Elanix Biotechnologies AG Total Liabilities Historical Data

The historical data trend for Elanix Biotechnologies AG's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elanix Biotechnologies AG Total Liabilities Chart

Elanix Biotechnologies AG Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Total Liabilities

Get a 7-Day Free Trial

0.05

6.67

6.37

1.93

2.48

Elanix Biotechnologies AG Semi-Annual Data
	Dec08	Dec09	Jun10	Dec10	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18
Total Liabilities	Get a 7-Day Free Trial															6.37	5.81	1.93	6.32	2.48

Elanix Biotechnologies AG Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Elanix Biotechnologies AG's Total Liabilities for the fiscal year that ended in Dec. 2018 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2.306	+	(0	+	0.174
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	2.48

Total Liabilities	=	Total Assets (A: Dec. 2018 )	-	Total Equity (A: Dec. 2018 )
	=	1.078	-	-1.403
	=	2.48

Elanix Biotechnologies AG's Total Liabilities for the quarter that ended in Dec. 2018 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2.306	+	(0	+	0.174
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	2.48

Total Liabilities	=	Total Assets (Q: Dec. 2018 )	-	Total Equity (Q: Dec. 2018 )
	=	1.078	-	-1.403
	=	2.48

Elanix Biotechnologies AG Total Liabilities Related Terms

Thank you for viewing the detailed overview of Elanix Biotechnologies AG's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Elanix Biotechnologies AG (FRA:ELN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elanix Biotechnologies AG (FRA:ELN) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Street-4, Georg-Glock, c/o HEUKING KÜHN LÜER WOJTEK, Dusseldorf, NW, DEU, 40474

Website

https://www.elanixbiotechnologies.ch

Elanix Biotechnologies AG is a tissue regeneration company. It develops and commercializes products for acute wound care, dermatological and gynecological applications as well as providing cell technology services. The company's operating segment include Regenerative Medicine and Cosmetic ointments. It generates maximum revenue from the Cosmetic ointments segment. Geographically, it derives a majority of revenue from Switzerland and also has a presence in the EU, and Taiwan.

Elanix Biotechnologies AG (FRA:ELN) Headlines

No Headlines